Centessa Pharmaceuticals (CNTA) Other financing activities (2021 - 2025)
Centessa Pharmaceuticals (CNTA) reported Other financing activities of -$5000.0 for Q4 2025, up 98.74% on a QoQ basis from -$396000.0 in Q1 2025.
Centessa Pharmaceuticals (CNTA) has 3 years of Other financing activities data on file, last reported at -$5000.0 in Q4 2025.
- Quarterly Other financing activities changed N/A year-over-year to -$5000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$5000.0 (up 98.74% YoY) and the FY2025 annual result came in at -$401000.0, changed N/A from the prior year.
- Other financing activities climbed to -$5000.0 in Q4 2025 per CNTA's latest filing, from -$396000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $12000.0 in Q4 2021 and bottomed at -$396000.0 in Q1 2025.
- The 3-year median for Other financing activities is -$261000.0 (2022), against an average of -$191400.0.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5,000.00 |
| Dec 31, 2025 | -5,000.00 |
| Mar 31, 2025 | -396,000.00 |
| Mar 31, 2025 | -396,000.00 |
| Mar 31, 2022 | -261,000.00 |
| Mar 31, 2022 | -261,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | -307,000.00 |
| Sep 30, 2021 | -307,000.00 |